-
Evidence for the Cumulative Impact of Social Determinants of Health (SDOH) on Cancer Mortality: A Scoping Review
Mar 10, 2025, 14:00 PM -
Analysis of Real-World Evidence Use Across FDA Submissions in 2022 and 2023
Mar 10, 2025, 14:00 PM -
Treatment Experience and Other Health and Social Characteristics Among Patients With Cancer From a Large US Population-Based Survey
Mar 10, 2025, 14:00 PM -
Cost-Effectiveness Analysis of Mirvetuximab Soravtansine in FRa-Positive Platinum-Resistant Ovarian Cancer in Japan
Mar 10, 2025, 14:00 PM -
Treatment Patterns Post-CAR T Cell Therapy in Patients With Hematologic Malignancies: A Real-World US Study
Mar 10, 2025, 14:00 PM -
Characterizing Cardiovascular Disease Patients in US Community Hospitals Using InsightsDB
Mar 10, 2025, 14:00 PM -
Impact of Cardiovascular, Renal and Metabolic Comorbidities on Activity and Health-Related Quality of Life in Patients with Metabolic Dysfunction-Associated Steatohepatitis in France, Italy, Germany, and Canada
Mar 10, 2025, 14:00 PM -
Budget Impact Analysis of Lanadelumab Versus C1 Inhibitor for Hereditary Angioedema Long Term Prophylaxis: A Brazilian Private Sector Perspective
Mar 10, 2025, 14:00 PM -
Characterization of Patients With Desmoid Tumors (DT) and Their Treatment Patterns Within an Academic Health System in the United States
Mar 10, 2025, 14:00 PM -
Relationship Between Event-Free Survival (EFS) and Overall Survival (OS) in Newly Diagnosed Patients With Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
Mar 10, 2025, 14:00 PM -
Overall Survival in People Living with HIV, Who Experienced Progressive Multifocal Leukoencephalopathy
Mar 10, 2025, 14:00 PM -
Evaluation of Chronic Conditions and Severe Outcomes in Adults Aged 18-59 Years With Medically Attended RSV Illness Using U.S. Commercial Claims Data
Mar 10, 2025, 14:00 PM -
Variation in Provider Reimbursement for Biosimilars and Reference Biologics by Commercial Payers
Mar 10, 2025, 14:00 PM -
Development and Validation of a Claims-Based Approach to Identify Patients with Metastatic Triple Negative Breast Cancer (mTNBC)
Mar 10, 2025, 14:00 PM -
Cost Effectiveness of Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients in China
Mar 10, 2025, 14:00 PM -
A Descriptive Analysis of Key Findings From the 2024-2025 ISPOR Student Interest Survey
Mar 10, 2025, 14:00 PM -
An Economic Model to Evaluate the Impact of Formulary Tier Increases for Apixaban on the Incidence and Cost of Clinical Events in Patients with Non-Valvular Atrial Fibrillation in the United States
Mar 10, 2025, 14:00 PM -
Development of Robust Comprehensive Code Lists to Ensure Consistency Across Global Real-World Evidence Studies
Mar 10, 2025, 14:00 PM -
Training and Validation of CARAaiTM: A Multi LLM Platform and Data Model to Address Oncology-Specific Challenges in Clinical Data Extraction
Mar 10, 2025, 14:00 PM -
Comparing Chemotherapy, Monotherapy, and Combination Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer Progression-Free Survival and Overall Survival: Systematic Review and Meta-Analysis
Mar 10, 2025, 14:00 PM
